Issue 25
Get instant access to latest e-book

latest newsRead more...

10

Dec 2016

AstraZeneca and Lilly enter into agreement to develop MEDI1814 for potential disease-modifying treatment for Alzheimer’s disease (AD)

AstraZeneca and Eli Lilly and Company today announced a worldwide agreement to codevelop MEDI an antibody selective for amyloidbeta A which is currently in Phase I trials as a potential diseasemodifying treatment for Alzheimers disease AD This agreement builds on the existing collaboratio..

10

Dec 2016

FDA has Granted Orphan Drug Designation Request for Biohaven Pharmaceutical's BHV-0223

Biohaven Pharmaceutical Holding Company Ltd announced that the US Food and Drug Administration FDA has granted the Companys orphan drug designation request covering its drug candidate BHV an orally dissolving tablet being developed for the treatment of Amyotrophic Lateral Sclerosis ALS also referred to as Lou Gehrigs disease This is the Companys th..

09

Dec 2016

Advanced Accelerator Applications Announces CMS Pass-Through Reimbursement Code for its First FDA Approved Drug NETSPOT(R)

Advanced Accelerator Applications SA an international specialist in Molecular Nuclear Medicine MNM today announced that the Centers for Medicare Medicaid Services CMS has granted NETSPOT Transitional PassThrough status under an Acode A for drug reimbursement effective January Additionally the same Healthcare Common ..

09

Dec 2016

Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK

Cardiome Pharma Corp NASDAQ CRME TSX COM announced that it has launched XYDALBA in the UK earlier than expected The European Medicines Agency EMA approved XYDALBA for the treatment of acute bacterial skin and skin structure infections ABSSSI in adults XYDALBA can be administered as either one mg dose or as a twodose ..

eventsRead more...

12 - 13

Dec 2016

09 - 10

Jan 2017

Optimizing Biologics Formulation Development

CHI Conferences
Hilton San Diego Bayfront

09

Dec 2016

09

Dec 2016

Abbott Raising Quarterly Dividend for 45th Straight Year

ABBOTT PARK Ill Dec PRNewswire The board of di..

TOP ARTICLES

  • 1

    Parenteral Preparations

    INTRODUCTION Parenteral preparations are defined as solutions suspensionsemulsions for injection or ..

knowledge bank

  • interviews

    Datwyler Pharma Packaging

    Senior Manager Global Scientific Affairs
    Renaud Janssen, Ph.D. is the Senior Manager of Global Scientific Affairs at Datwyler Pharma Packaging. He frequently presents on international conferences on subjects related to elastomeric and aluminium/plastic closures for pharm..

  • Articles

    Parenteral Preparations

    INTRODUCTION Parenteral preparations are defined as solutions suspensionsemulsions for injection or infusion powders for injection or infusion gels for injection andimplants They are sterile preparations intended to be administrated directly into the systemic circulation in human or animal body They are required like any pharmaceutical dosage forms to meet the pharmaceutical quality standards as ..

  • Research Insights

    Open For Collaboration: An Academic Platform For Drug Discovery And Development At Scilifelab

    Abstract Swedish pharmaceutical industry and research Being a small country with only million inhabitants Sweden has a proud history of successful organic growth of its pharmaceutical industry with companies such as Kabi the first company to license Genentechs recombinant DNA technology later overtaken by Pharmacia subsequently merging with Upjohn and later being closed as a part of Pfizer Hssle bought by Astra and Astra merged with Zeneca to ..

editorial Section

  • Competing on Alignment

    SWOT is both the most powerful and least understood strategic management tool Used correctly it translates the outputs of many other market analyses into a small number of key issues..

  • Future Trends in Ion Channel and Solute Transporter Drug Discovery

    Gene family members of the ion channel and solute transporter SLC families represent both historical targets of pharmaceutical significance and serve as exciting opportunities for current and future therapeutic development The common property of ion movement for many of the SLCs lends itself to considering platforms used in ion channel research to enable early drug discovery In addition the convergence of advances in both genetic analysis and assay technology bodes well for the identification of the next generation of ion channel and transporterbased drugs in the near future..

  • Issues & Concerns in Conducting Clinical Trials in India

    Issues like approval delays deficiencies of functioning of CROs and other stake holders liabilities and compensation to injured subjects insurance issues etc still remain in India which has made multinational companies to rethink on opting for India to conduct clinical trials in India recently There is a need for a law to ensure that the people who undergo clinical trials are not exploited and should be well informed about risk as well to provide..

  • Innovation Challenges in Manufacturing

    Most firms in the pharmaceutical industry think globally to expand demand for their products There are amenities from which firms leverage to launch a strategy to gain global market share These amenities include the regulatory dimension which helps reassign resources within and outside the firm..

  • Quality by Design

    The article presents a novel approach to applying Quality by Design QbD principles to the development of analytical methods Common critical parameters in HPLC gradient time temperature pH of the aqueous eluent and stationary phase are evaluated within the Quality by Design framework It is useful for the robust analytical method development and Design Space optimisation..

  • Peptides Remain a Growth Story

    Cloud solutions offer immediate returns in improving operational performance and reducing costs Multiple approaches to cloud solutions will be needed to satisfy life science industry needs complicating the development of a coherent cloud strategy..

TOP